Pfizer Inc. announced the expiration and results of its previously announced (i) offer to purchase for cash (the “Tender Offer”) any and all of its outstanding €2,000,000,000 5.750%. Notes due 2021 (the “2021 Notes”) from holders thereof, and related (ii) solicitation of consents (“Consents”) to amend the 2021 Notes and the indenture pursuant to which the 2021 Notes were issued (the “Indenture”) to shorten the required notice in the case of an optional redemption by Pfizer to not less than seven days nor more than 60 days (the “Proposed Amendments”) (the “Consent Solicitation” and together with the Tender Offer, the “Offer”). The Offer was made on the terms and subject to the conditions set forth in the Offer to Purchase and Consent Solicitation Statement dated December 7, 2017 (the “Offer to Purchase”). The Offer expired at 11:59 p.m. (New York time) on January 5, 2018 (the “Offer Expiration Date”). On the terms and subject to the conditions set forth in the Offer to Purchase, the aggregate principal amount of 2021 Notes tendered and not validly withdrawn prior to the Offer Expiration Date. (1) Includes €834,000,000 aggregate principal amount of 2021 Notes validly tendered at or prior to the Early Tender and Consent Date and not validly withdrawn and purchased by Pfizer on the Early Settlement Date of December 28, 2017. (2) Payable in cash per each €1,000 principal amount of the 2021 Notes validly tendered at or prior to the Early Tender and Consent Date and not validly withdrawn and accepted for purchase. The Early Tender and Consent Payment is included in the Total Consideration. Holders tendering after the Early Tender and Consent Date will not receive the Early Tender and Consent Payment. (3) Payable in cash per each €1,000 principal amount of the 2021 Notes validly tendered after the Early Tender and Consent Date and at or prior to the Offer Expiration Date and not validly withdrawn and accepted for purchase. The company expects to accept all €24,700,000 additional 2021 Notes validly tendered since 5:00 p.m. (New York Time) on December 20, 2017 (the “Early Tender and Consent Date”) and at or prior to the Offer Expiration Date. The “Final Settlement Date” in respect of the 2021 Notes validly tendered and not validly withdrawn after the Early Tender and Consent Date but at or prior to the Expiration Date is expected to be January 10, 2018. Holders whose 2021 Notes were validly tendered at or prior to the Early Tender and Consent Date and not validly withdrawn received a cash payment representing the Total Consideration plus Accrued Interest (as set forth in the Offer to Purchase) on those 2021 Notes. Holders whose 2021 Notes were validly tendered after the Early Tender and Consent Date and at or prior to the Offer Expiration Date will only be eligible to receive a cash payment representing the Purchase Price plus Accrued Interest (as set forth in the Offer to Purchase) on those 2021 Notes. The amount tendered does not constitute at least a majority of the aggregate principal amount of the outstanding 2021 Notes (the “Required Consents”). The company reconfirms it has elected to waive the condition to the Offer that the Required Consents be obtained and will accept for payment 2021 Notes that were validly tendered and not validly withdrawn after the Early Tender and Consent Date and at or prior to the Offer Expiration Date. However, because the Required Consents were not received, Pfizer will not execute a supplemental indenture to the Indenture and the Proposed Amendments will not take effect.